RedHill's Oral Broad-Acting Antiviral, Opaganib, Granted New COVID-19 Treatment PatentPRNewsWire • 10/19/22
RedHill's Oral Broad-Acting Antivirals, Opaganib and RHB-107, Inhibit Dominant Omicron Sub-Variant BA.5PRNewsWire • 10/03/22
RedHill Biopharma Announces EU Orphan Drug Designation for RHB-204 for NTM InfectionsPRNewsWire • 08/17/22
RedHill Announces New H. pylori and COVID-19 Data Publication and Presentations at Leading Upcoming Scientific ConferencesPRNewsWire • 07/12/22
RedHill Biopharma Ltd. (RDHL) CEO Dror Ben-Asher on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 06/23/22
RedHill Biopharma Announces Q1/22 Highlights: On Track for Positive Cash from Operations in H2/22PRNewsWire • 06/23/22
RedHill Biopharma to Host First Quarter 2022 Financial Results and Operational Highlights Webcast on June 23, 2022PRNewsWire • 06/17/22
RedHill Biopharma Announces $15 Million Registered Direct Offering with a Leading Healthcare InvestorPRNewsWire • 05/09/22
Redhill Biopharma Ltd. (RDHL) Could Find Support Soon, Here's Why You Should Buy the Stock NowZacks Investment Research • 04/14/22
RedHill Biopharma Says Opaganib Can Potentially Work Against COVID-19 Omicron SubvariantsBenzinga • 04/11/22
RedHill Reports Potent Inhibition of Omicron with Oral COVID-19 Drug Candidate Opaganib In VitroPRNewsWire • 04/11/22
RedHill Biopharma Ltd Announces Potent Omicron Inhibition with RedHill's OpaganibAccesswire • 04/11/22
RedHill Biopharma Ltd. (RDHL) CEO Dror Ben-Asher on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/17/22
RedHill Biopharma Reports Operational Highlights and Fourth Quarter & Full Year 2021 Financial ResultsPRNewsWire • 03/17/22